Healthcare, Regulatory and Reimbursement Landscape - AustraliaGlobalData
July 24, 2012
177 Pages - SKU: GBDT4856581
Additional InformationAustralia’s Healthcare Regulations Struggle to Keep up with Population Ageing
The growing elderly population and its associated disease burden add to the economic challenges faced by the Australian government, according to a new report by healthcare experts GlobalData.
The new report states that the Australian healthcare market is driven by universal healthcare coverage and good access to facilities such as government-subsidized medicines. However, the growing elderly population and its associated disease burden are set to challenge Australia’s ability to maintain this level of care.
Universal healthcare coverage, good access to healthcare facilities and subsidized essential drugs are the distinguishing features of the Australian healthcare system. Medicare offers universal access to healthcare and covers the entire population through programs such as the Pharmaceutical Benefits Scheme (PBS), the Australian Childhood Immunization Register, and the Australian Organ Donor Register. Medicare ensures access to free or low-cost medical and hospital care, and a government subsidy for drugs dispensed under PBS is available.
However, the government is implementing major PBS reforms in order to reduce its healthcare expenditure; such reforms include a payment of $1.40 to pharmacies for substitutable and premium-free PBS-subsidized drugs, introduced in July 2010.
Australia boasted a population of approximately 22.4 million in 2010, and the population aged 65 years and older is projected to account for approximately 18.3% of the population by 2020. This is due to a longer life expectancy, improved healthcare facilities, and strong financial and healthcare support by the government. The government has a high level of financial and policy responsibility for health services, such as hospitals, public health, and drug availability. As the elderly population increases, so too does the Australian governments cost burden, which is due to overwhelm state finances in the not too distant future.
Despite these problems, the rapidly growing elderly population and increased awareness of chronic diseases in Australia guarantee that the country’s well-defined regulatory guidelines and increasing pharmaceutical R&D expenditure will lead to strong growth in the medical care and diagnostic markets. Australia has a transparent and efficient regulatory system to facilitate the approval of pharmaceutical products and medical devices. The main regulatory authority for pharmaceutical products and medical goods is the Therapeutic Goods Administration (TGA), a division of the Department of Health and Ageing. The TGA's overall purpose is to protect public health and safety by regulating therapeutic goods that are either supplied through imports, manufactured in Australia or exported from Australia. Market authorization of a new drug or medical device requires the execution of good laboratory practice and compliance with TGA standards. Therefore, Australia’s growing elderly population may serve a purpose in fuelling medical discoveries.
The pharmaceutical market in Australia was valued at approximately $14.9 billion in 2010 and is projected to reach approximately $30.5 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 7.4%.
*Healthcare, Regulatory and Reimbursement Landscape – Australia
This report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Australia. It identifies key trends, and most importantly, provides valuable insights into the trends and segmentation of the pharmaceutical and medical devices market.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
More Pricing reports by GlobalData
Healthcare, Regulatory and Reimbursement Landscape - Portugal by GlobalData
Healthcare, Regulatory and Reimbursement Landscape - PortugalSummaryGlobalData, the industry analysis specialist, has released its new report, “Healthcare, Regulatory and Reimbursement Landscape - Portugal”. The report ...
Healthcare, Regulatory and Reimbursement Landscape - Norway by GlobalData
Healthcare, Regulatory and Reimbursement Landscape - NorwaySummaryGlobalData, the industry analysis specialist, has released its new report, “Healthcare, Regulatory and Reimbursement Landscape - Norway”. The report ...
Healthcare, Regulatory and Reimbursement Landscape - Finland by GlobalData
Healthcare, Regulatory and Reimbursement Landscape - FinlandSummaryIndustry analysis specialist GlobalData has released its latest report, “Healthcare, Regulatory and Reimbursement Landscape - Finland”. An essential source ...
Healthcare, Regulatory and Reimbursement Landscape - Austria by GlobalDataSee all reports like this >>
Healthcare, Regulatory and Reimbursement Landscape - AustriaSummaryIndustry analysis specialist GlobalData has released its latest report, “Healthcare, Regulatory and Reimbursement Landscape - Austria”. An essential source ...
More Australia Pricing reports
Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide by JustPharmaReports.com
Managed entry agreements apply to an increasing number of new, innovative drugs in a growing number of markets. They are designed to share the risk ...
The Pharmaceutical Market: Australia by Espicom Healthcare Intelligence
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of ...
Reforms to the Pharmaceutical Benefits Scheme in Australia by Datamonitor
IntroductionAs further statutory price cuts and “expanded and accelerated” price disclosure is applied to substitutable medicines by the Australian Pharmaceutical Benefits Scheme (PBS), downward pricing ...
Pharmaceutical Pricing and Reimbursement in Australia by Decision ResourcesSee all reports like this >>
With the routine use of health economic evaluation in reimbursement decision making, an extensive and aggressive reference pricing system, and some of the lowest branded ...
More Australia reports
D&B Country RiskLine Report: Australia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Australian Cloud Computing Research Program 2011: A Strategic Analysis of the Australian Data Centre Infrastructure and Services Market by Frost & Sullivan
This report analyses end-user perception, adoption and usage of data centre infrastructure and services in Australia. Through detailed end-user interviews, the Australian data centre infrastructure ...
D&B Country Report: Australia by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Australia: Country Profile by MarketLineSee all reports like this >>
INTRODUCTIONThis report provides a detailed analysis on Australia, providing an overview of its political, economic and business environment, represented both textually and in graph and ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Regulation & Policy
- Insurance & Managed Care
- General Insurance & Managed Care
- Life Sciences
- Medical Devices
- Medical Devices
- Manufacturing, Packaging & Detailing
- Global Healthcare Policy Analysis 2012 – Regulatory, Pricing, and Reimbursement Assessment
- Healthcare, Regulatory and Reimbursement Landscape - South Korea
- Healthcare, Regulatory and Reimbursement Landscape Vietnam
- Healthcare, Regulatory and Reimbursement Landscape Russia
- Healthcare, Regulatory and Reimbursement Landscape - Indonesia